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1. Introduction 
Alzheimer disease (AD) is known as a form of type III diabetes due to its similar cellular 
responses and pathogenesis. Insulin alters normal brain function and peripheral glucose 
metabolism, and conditions that are related to insulin dysregulation, such as obesity, 
diabetes mellitus, and cardiovascular disease, have potentially harmful effects on brain 
function. Many reports have demonstrated that insulin resistance increases age-related 
memory impairments and is a risk factor for AD. The molecular and cellular link between 
insulin resistance and AD, however, is unknown. We discuss the potential mechanisms of 
these metabolic disorders in the pathogenesis of AD. Glucose homeostasis is critical for 
energy maintenance, neurogenesis, neuronal survival, and synaptic plasticity, which are 
required for learning and memory. During insulin resistance, one develops reduced 
sensitivity to insulin, resulting in hyperinsulinemia, and this impairment in insulin signaling 
mediates the pathogenesis of AD, which manifests as brain inflammation, oxidative stress, 
alterations in amyloid beta (Aǃ) levels, and cell death. Human and experimental animal 
studies have noted that drugs that modulate insulin resistance decrease the accumulation of 
Aǃ in the brain and the cognitive impairments that are associated with AD. Therapeutic 
strategies that target the link between insulin resistance and AD might benefit the 
development of future AD drugs.  
2. Insulin signaling  
2.1 Introduction 
Insulin is a peptide hormone that comprises 51 amino acids and is synthesized in and 
secreted from pancreatic ǃ-cells in the islet of Langerhans (Huang et al., 2010). Its rapid 
release is generally triggered by increased levels of glucose in the blood, despite other 
mechanisms that release insulin; normal blood glucose levels range from 4.4 to 6.1 mmol/L 
(82 to 110 mg/dL). 
Of its many functions, the most significant effects of insulin are its promotion of cellular 
growth and differentiation, activation or repression of transcription, and regulation of 
protein kinases and phosphatases (Saltiel and Pessin, 2002). Defects in insulin signaling can 
affect many diseases, such as type 2 diabetes mellitus (T2DM), metabolic syndrome, and 
Alzheimer disease (AD). Although most studies have examined the function of insulin and 
the dysregulation of insulin secretion or insulin receptor signaling in peripheral tissue, it has 
recently been reported to cause serious mental illness (Huang et al., 2010).  
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2.2 General effects of insulin signaling  
Insulin increases glycogen and lipid synthesis in liver and muscle cells and simultaneously 
inhibits glycogenolysis and gluconeogenesis in the liver during feeding (Saltiel and Kahn, 
2001). These actions are mediated by its binding to membrane-bound insulin receptors (IRs), 
members of the tyrosine kinase receptor family (Saltiel and Pessin, 2002). The binding of 
insulin to the alpha subunit of IR induces a conformational change, resulting in the 
autophosphorylation of tyrosine residues in the beta subunit of the receptor (Van 
Obberghen et al., 2001). This ligation leads to the subsequent tyrosine phosphorylation of 
insulin receptor substrates 1-4 (IRS1-4), Shc, Gab-1, Cbl, and APS (Saltiel and Pessin, 2002), 
and activates downstream cytoplasmic effectors, such as the lipid kinase 
phosphatidylinositol 3-kinase (PI 3-kinase) and mitogen-activated protein kinase (MAPK) 
(Cole et al., 2007; Plum et al., 2005). 
During insulin-mediated glucose uptake, the phosphorylated residues of insulin receptor 
and IRS1, 2, and 3 are recognized by the Src homology 2 (SH2) domain (Bevan, 2001) of the 
p85 regulatory subunit of PI 3-kinase. The catalytic subunit of PI 3-kinase, p110, 
phosphorylates phosphatidylinositol (4,5) bisphosphate (PtdIns(4,5)P2), leading to the 
formation of Ptd(3,4,5)P3 (Lizcano and Alessi, 2002). Ptd(3,4,5)P3 then binds to the plasma 
membrane and associates with phosphoinositol-dependent kinase-1 (PDK-1) and induces 
the phosphorylation and activation of protein kinase B (PKB)/Akt, a serine-threonine 
kinase. Activated Akt enters the cytoplasm, where it evokes the phosphorylation and 
inactivation of glycogen synthase kinase 3 (GSK3), which promotes glycogen synthesis. 
By activating PI3-kinase and AKT (Lizcano and Alessi, 2002), insulin affects the 
translocation of glucose transporter 4 (GLUT4) from intracellular stores to the plasma 
membrane: When insulin concentrations are low, GLUT4 exists in cytoplasmic vesicles. 
After insulin binds to its receptors, GLUT4-containing vesicles fuse with the plasma 
membrane, and the newly inserted GLUT4 takes up glucose efficiently. In parallel, there is a 
PI 3-kinase independent pathway that recruits GLUT4 to the plasma membrane, led by the 
phosphorylation of the proto-oncogene Cbl, which is associated with the adaptor protein c-
Cbl-associated protein (CAP) (Saltiel and Kahn, 2001). 
Insulin promotes the uptake and synthesis of fatty acids in the liver and prevents lipolysis 
by inhibiting the intracellular lipase that hydrolyzes triglycerides to release fatty acids. 
Although insulin promotes the synthesis of glycogen in the liver, further synthesis is 
suppressed when the liver is saturated with glycogen. Any additional glucose that is taken 
up is then shunted into pathways that lead to fatty acid synthesis (Saltiel and Kahn, 2001). 
One study has indicated that lipid synthesis requires increased expression of the 
transcription factor steroid regulatory element-binding protein (SREBP)-1c (Shimomura et 
al., 1999), which is synthesized as a membrane protein in the endoplasmic reticulum (ER) 
(Sato, 2010). Insulin is believed to induce SREBP-1c proteolytic activity and, consequently, 
insulin-mediated lipogenesis (Sato, 2010). Further, insulin inhibits lipid metabolism by 
decreasing cellular concentrations of cAMP through activation of a cAMP-specific 
phosphodiesterase in adipocytes (Kitamura et al., 1999). 
Insulin stimulates amino acid uptake into cells, inhibits protein degradation, and promotes 
protein synthesis (Saltiel and Kahn, 2001) by stimulating components of the translational 
machinery, including eukaryotic initiation factors (elFs) and eukaryotic elongation factors 
(eEFs) (Proud, 2006). This entails the activation of PKB, leading to the phosphorylation and 
inactivation of GSK3, which in turn promotes phosphorylation and inhibition of a guanine 
nucleotide exchange factor, eIF2B, to regulate the initiation of translation (Proud, 2006). 
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Moreover, PKB phosphorylates the tuberous sclerosis complex 1 (TSC1)-TSC2 complex, 
relieving its inhibition of the mammalian target of rapamycin (mTOR) (Proud, 2006), which 
promotes protein synthesis through p70 ribosomal S6 kinase (p70S6k) and inhibition of eIF-
4E binding protein (4E-BP1), and thereby governs ribosomal protein translation (Proud, 
2006). 
2.3 Insulin in the brain 
The brain is the primary consumer of glucose, requiring two-thirds of total circulating 
glucose daily (Peters, 2011); thus, the regulation of glucose homeostasis by insulin in the 
central nervous system (CNS) is paramount for normal brain function. Insulin, by a 
saturable transport process that is mediated by insulin receptor, can cross the blood-brain 
barrier (BBB), which governs the transduction between the CNS and peripheral tissues 
(Neumann et al., 2008). Although insulin is synthesized locally in the brain (Banks et al., 
1997; Devaskar et al., 1994; Rulifson et al., 2002), its function is unknown. 
IRs in the CNS are widely expressed throughout the brain in neurons and glial cells, at 
particularly high concentrations in the cerebral cortex, hippocampus, hypothalamus, and 
olfactory bulb (Neumann et al., 2008). They have disparate functions, molecular weights, 
and structures from IRs in peripheral organs (Heidenreich et al., 1983), but it is unknown 
whether the counter effects of insulin in the CNS compared with those in peripheral tissues 
are attributed to such differences. Insulin increases glucose and inhibits feeding in the CNS, 
but decreases glucose and stimulates feeding in peripheral tissue (Florant et al., 1991). A 
recent report observed that impaired brain insulin activity might affect unrestrained 
lipolysis that initiates and exacerbates type 2 diabetes mellitus in humans (Scherer et al., 
2011). 
2.4 Role of insulin in cognitive function  
In humans, brain insulin enhances learning, memory, and, in particular, verbal memory 
(Benedict et al., 2004). Insulin signaling in the limbic system and hypothalamus is especially 
important for cognitive function (Zhao et al., 1999), independent of changes in peripheral 
glucose (Craft et al., 1999; Kern et al., 1999). These functions have been supported by 
evidence that insulin modulates the concentrations of neurotransmitters, which influence 
cognition, such as Ach (acetylcholine) (Kopf and Baratti, 1999). Insulin also alters synaptic 
plasticity by regulating the endocytosis of 3-hydroxy-5-methylisoxazole-4-propionic acid 
(AMPA) receptor, which causes long-term depression (LTD) of excitatory synaptic 
transmission in the hippocampus and cerebellum (Huang et al., 2003; Man et al., 2000; Wang 
and Linden, 2000), and by enhancing N-methyl-D-aspartate (NMDA) receptor-mediated 
synaptic transmission at hippocampal CA1 synapses (van der Heide et al., 2005).  
2.5 Insulin-like growth factor (IGF) 
Insulin-like growth factors are polypeptides that are similar in sequence to proinsulin 
(Clemmons, 2007). Insulin-like growth factor 1, which stimulates cell growth and 
proliferation, especially in nerve cells, binds to IGF receptor and IRs (Jones et al., 2009). IGF-
1 functions similarly to insulin receptor. IGF-1, a tyrosine kinase, initiates signaling cascades 
through IRS and enhances insulin activity (Clemmons, 2007). 
Deficiency of or irresponsiveness to IGF-1 causes not only growth failure but also 
dyslipidemia (Twickler et al., 2003), insulin resistance (Conti et al., 2002; Twickler et al., 
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2003), and obesity (Rasmussen et al., 1995). According to recent longitudinal studies, these 
phenotypes are closely related to a high risk of neurodegenerative disorders, such as 
dementia and AD (Luchsinger et al., 2004; Ott et al., 1996; Ronnemaa et al., 2008). Similarly, 
mice in which IGF-1 has been deleted develop increased Aǃ levels in the brain, suggesting 
that IGF-1 promotes the clearance of Aǃ (Carro et al., 2002). Moreover, IGF-1 mediates 
transient site-selective increases in tau phosphorylation—hyperphosphorylated tau is a 
pathological hallmark of AD—in primary cortical neurons via GSK-3 pathways (Lesort and 
Johnson, 2000).  
  
 
 
Fig. 1. Schematic diagram of the effects of peripheral insulin resistance on insulin, insulin-
degrading enzyme (IDE) and Aǃ levels. Peripheral insulin resistance and hyperinsulinemia 
triggers an excess release of FFA from adipocytes to liver and muscles. A three-fold increase 
of FFAs reduce insulin-dependent skeletal muscle glucose uptake by 50% (Roden et al., 
1996), thereby hampering further insulin signal transduction (Hotamisligil et al., 1996; 
Schinner et al., 2005). In addition, Increased peripheral FFA levels invoke elevations in 
TNFǂ in the periphery and in the CNS, which may result in increased accumulation of Aǃ. 
Chronic elevations in plasma Aǃ may result in increased transport of Aǃ into the brain. In 
contrast, peripheral hyperinsulinemia decrease insulin transport into the CNS. Low insulin 
level in CNS, and low level of IDE may contribute to the formation of senile plaques via 
disability to degrade Aǃ peptides (Jones et al., 2009), further promoting intraneuronal Aǃ 
accumulation, which is the hallmark of AD. <modified from Craft’s paper (Craft, 2007)> 
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2.6 Insulin-degrading enzyme (IDE) 
Insulin-degrading enzyme is the chief enzyme that degrades excess insulin and other 
substrates, including Aǃ, a peptide that is implicated in the pathogenesis of AD (Wang et al., 
2010). IDE knockout mice experienced decreased Aǃ degradation, hyperinsulinemia, and 
hyperglycemia (Farris et al., 2003). As insulin levels rise, IDE expression increases to prevent the 
chronic activation of insulin (Zhao et al., 2004). Reduced IDE activity might contribute to the 
formation of senile plaques through the inability to degrade Aǃ peptides (Jones et al., 2009). 
3. Insulin resistance 
3.1 Definition of insulin resistance 
Insulin resistance is a physiological condition in which one loses or reduces his sensitivity to 
insulin—that is, it becomes less effective at lowering glucose levels in the blood. There are 
several representative phenotypes of insulin resistance that are used to diagnose diabetes, 
such as hyperinsulinemia (elevated levels of insulin that are required to maintain normal 
glucose levels in the bloodstream) and hyperglycemia (elevated glucose levels in the 
bloodstream that result from the failure of insulin to mediate glucose uptake or insufficient 
production of insulin by ǃ-cells). Thus, insulin resistance reduces glycogen storage in 
muscle and fat cells and decreases hepatic glucose uptake. 
High cortisol and uric acid levels and low vitamin D levels (Chiu et al., 2004; Vuorinen-
Markkola and Yki-Jarvinen, 1994) are believed to be dietary conditions that precipitate 
insulin resistance. In addition, insulin resistance is closely related to obesity, hypertension, 
polycystic ovarian syndrome, dyslipidemia, and atherosclerosis (Saltiel and Pessin, 2002). 
3.2 Peripheral effects of insulin resistance 
Advanced glycation end products (AGEs) production is a pathological phenotype that 
results from hyperglycemia (Jager et al., 2007). Activation of the jun-N-terminal kinase 
(JNK) pathway by the binding of AGEs to their receptor (RAGE) leads to serine 
phosphorylation of IRS proteins and disrupts the imbalance in glucose levels further (Han et 
al., 2011). In addition to excess AGE production, prolonged hyperglycemia activates the 
transcription factor nuclear factor kappa B (NF-kB), which regulates proinflammatory and 
antiapoptotic pathways by modulating the transcription of cytokine and antioxidant genes 
(Baeuerle and Baltimore, 1996); it also controls the expression of genes that mediate immune 
responses and proliferation.  
Peripheral insulin resistance mediates the progression to hyperglycemia and affects other 
functions of insulin. In particular, it affects reduced uptake of circulating lipids and 
increased hydrolysis of stored triglycerides. Such dysfunctional lipid homeostasis has been 
identified as a significant trigger of insulin resistance (Jones et al., 2009) 
Because insulin resistance is linked to metabolic syndrome, which is generally characterized 
as overweightedness and obesity, and is often observed in persons with hyperglycemia and 
visceral adiposity, visceral fat is believed to accelerate insulin insensitivity, since visceral fat 
is less sensitive to the antilipolytic activity of insulin than subcutaneous fat (Jones et al., 
2009), thereby triggering excessive release of free fatty acids (FFAs) (Schulingkamp et al., 
2000) into the bloodstream. FFAs increase 3-fold above basal levels, reducing insulin-
dependent skeletal muscle glucose uptake by 50% (Roden et al., 1996). This phenomenon, a 
direct cause of insulin resistance, induces inhibits serine phosphorylation of IRS and 
decreases its chances of binding to insulin receptor, further hampering insulin signaling 
(Hotamisligil et al., 1996; Schinner et al., 2005). 
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3.3 Central insulin resistance 
As discussed, an abnormality in peripheral insulin is a risk factor for memory loss and 
neurodegeneration. In addition, chronic exposure of neurons to high insulin levels has a 
negative impact on memory, according to animal model studies. Chronic hyperinsulinemia 
impairs BBB function and IR activity and reduces insulin transport to the brain (Strachan et 
al., 1997). In contrast, some studies have noted that acute increases in brain insulin enhance 
memory (Craft et al., 1999; Park et al., 2000).  
4. Link between insulin resistance and Alzheimer disease 
Many studies have suggested that patients with diabetes have a higher risk of AD. Luchsinger 
et al. found that hyperinsulinemia increased risk for AD (Luchsinger et al., 2004). Also, it has 
been shown that high levels of insulin and insulin resistance are associated with a higher risk 
of AD in Rotterdam study, a population-based cohort study (Ott et al., 1999; Schrijvers et al., 
2010). Although relationship between diabetes and AD remains controversial (Profenno et al., 
2010), the abnormalities in insulin metabolism, which influence the onset of AD 
mechanistically, are believed to mediate AD through their influence on the synthesis and 
degradation of Aǃ, tau hyperphosphorylation, oxidative stress and/or inflammation. 
4.1 Impaired insulin/IGF-1 system in the AD brain 
By positron emission tomography (PET) of early-stage AD and mild cognitive impairment 
(MCI), glucose uptake and metabolism decline significantly in the cortex (Jagust et al., 1991). 
According to another study, cerebral glucose utilization and blood flow fall by 45% and 
18%, respectively, in the early stages of AD. In late-stage AD, cerebral blood flow is reduced 
by 65% (Hoyer and Nitsch, 1989). These data indicate that brain metabolism is altered in the 
AD brain, resembling T2DM. In addition, AD patients experience decreases in insulin in the 
CSF, reflecting dysregulation in insulin transport to the brain (Messier and White, 1987). 
The AD brain also exhibits reduced expression of IR and IGF-1R, IRS, and trophic factors 
(Steen et al., 2005). IGF-1R expression decreases in AD brains in proportion to disease 
severity, and IGF-1 mRNA levels decline in late-stage AD (Frolich et al., 1998). IRS1/2 
expression is decreased in the AD brain (Bosco et al., 2011; Squire, 1986). Because IRS1 and 2 
regulate insulin and IGF-1 signaling, these findings suggest that insulin/IGF-1 signal 
transduction is altered in the AD brain. 
There is much evidence of altered insulin signaling in AD. Inhibition of insulin/IGF-1 
signaling in AD blocks the Wnt pathway (Doble and Woodgett, 2003), which mediates 
normal physiological processes in animals (Gogolla et al., 2009). Further, decreased PI3K 
signaling reduces GLUT4 translocation, inhibiting glucose uptake (Johnston et al., 2003). 
Since the brain depends on glucose as an energy source, altered glucose metabolism reduces 
the synthesis of acetyl-CoA and, ultimately, acetylcholine, an important neurotransmitter 
(Gibson et al., 1981). This decrease disrupts synaptic transmission and, consequently, 
impairs memory (Craft et al., 2003).  
4.2 Insulin resistance and APP processing 
Recent studies have indicated that abnormalities in insulin metabolism mediate the onset of 
AD through their influence on the synthesis and degradation of Aǃ peptides (Table 1). 
Insulin significantly upregulates extracellular levels of Aǃ40 and Aǃ42 peptides through 
acceleration of amyloid precursor protein (APP)/Aǃ trafficking from the Golgi/trans-Golgi 
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network (TGN), a major site of Aǃ generation, to the plasma membrane (Gasparini et al., 
2001). Also, certain downstream signaling pathways of IR might also regulate the generation 
of Aǃ peptides by modulating the expression or activity of ǃ-secretase or Ǆ-secretase (Phiel 
et al., 2003; Zhang et al., 2011), major components of APP processing (Edbauer et al., 2003; 
Vassar et al., 1999).  
Under AD-like conditions, the expression levels of the neurotrophin receptors TrkA 
(tyrosine kinase receptor A) and p75NTR (p75 neurotrophin receptor) change markedly,  
increasing Aǃ production by stabilizing ǃ-secretase through the activation of 
sphingomyelinase (Puglielli et al., 2003). Chronic treatment of neuronal cells with IGF-1 
(which induces insulin resistance) results in alteration in expression of TrkA and p75NTR, 
as in AD brains, increasing Aǃ production (Costantini et al., 2006). Aǃ is a ligand of p75NTR 
(Yaar et al., 1997), and Aǃ stimulates p75NTR-mediated cell death in vitro and in vivo 
(Coulson, 2006; Sotthibundhu et al., 2008).  
 
 
 
Fig. 2. Amyloid plaque and neurofibrillary tangles as hallmarks of Alzheimer disease (AD). 
AD is a progressive neurodegenerative disease characterized by senile plaques, 
neurofibrillary tangles and neuronal loss. Abnormal aggregates of amyloid-beta peptide 
(Aǃ) are found in extracellular senile plaques and associated with neurodegeneration in AD. 
Neurofibrillary tangles are aggregates of the microtubule-associated protein (MAP) tau 
protein which is hyperphosphorylated by kinases and accumulated inside the neurons 
themselves. 
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In AD brains, Aǃ accumulates on not only alterations in Aǃ generation but also dysfunction 
of Aǃ clearance. Several mechanisms of Aǃ clearance have been examined: 1) Enzymatic 
degradation by microglia or endopeptidases, such as IDE (Qiu and Folstein, 2006), 
neprilysin (Iwata et al., 2000), endothelin-converting enzyme (ECE) (Eckman et al., 2003), 
angiotensin-converting enzyme (ACE) (Lehmann et al., 2005), matrix metalloproteinase-9 
(MMP-9), and plasmin (Nalivaeva et al., 2008); 2) Influx into receptor-mediated transport 
across the BBB primarily via RAGE (Deane et al., 2003; Han et al., 2011); and 3) Receptor-
mediated BBB transport by binding to low-density lipoprotein receptor-related protein-1 
(LRP1) after ligation with apolipoprotein E (APOE) or ǂ2-macroglobulin (ǂ2M), to be 
delivered to peripheral sites of degradation (Shibata et al., 2000). 
With regard to insulin resistance, insulin induces the accumulation of Aǃ by limiting Aǃ 
degradation through direct competition for IDE. IDE is a zinc metalloendopeptidase that 
preferentially cleaves proteins that tend to form ǃ-pleated sheet-rich amyloid fibrils, such as 
Aǃ peptides (Qiu and Folstein, 2006). IDE activity in the brain correlates negatively with Aǃ 
levels (Farris et al., 2003), and IDE expression is decreased in the AD brain (Cook et al., 
2003). Insulin regulates the levels of IDE, and insulin resistance reduces Aǃ clearance by 
down-regulating IDE expression or competing with it for binding (Farris et al., 2003; Ho et 
al., 2004). A recent report has indicated that Aǃ oligomers disrupt IR signaling, resulting 
from a rapid and substantial loss of neuronal IRs on dendrites by Aǃ oligomer (Zhao et al., 
2008). There is also evidence that Aǃ reduces insulin binding to IRs and induces insulin 
resistance (Xie et al., 2002). 
4.3 Insulin resistance and tau phosphorylation 
AD is a multifactorial disease in which protein alterations, oxidative stress, inflammation, 
dysregulated immunity, impaired neuronal-glial communication, and increase of neurotoxic 
agents triggering neuronal death. AD is defined by Aǃ pathology (Aǃ plaques) and tau 
pathology [neurofibrillary tangles (NFTs)], but whether tau mediates AD pathology has 
been discussed for many years. Nevertheless, there is increasing evidence that when tau 
proteins assume pathological forms, they compromise neuronal function and affect cell 
death. These results suggest that tau is an important mediator of Aǃ toxicity and AD 
pathology (Pritchard et al., 2011).  
Microtubule (MT)-associated protein (MAP) tau is the major MT-associated phosphor-
protein in normal neuronal cells (Cleveland et al., 1977). Normally, tau proteins assemble 
with tubulin to stabilize microtubules and vesicular transport. Neurofibrillary tangles are 
hyperphosphorylated and aggregated forms of tau proteins. When it is 
hyperphosphorylated, tau becomes insoluble and lacks affinity for microtubules, leading to 
neurodegeneration (Iqbal et al., 2005). 
The kinases that regulate tau phosphorylation are grouped according to specificity: 1) 
proline-directed protein kinases, such as cyclin-dependent kinase 5 (CDK5), glycogen 
synthase kinase 3ǃ (GSK3ǃ), MAPK1, p38, JNK, and ERK2; and 2) nonproline-directed 
protein kinases, such as cAMP-dependent protein kinase A (PKA), PKC, CaMKII, CKII, and 
MAP/microtubule affinity-regulating kinase (MARK) (Baudier et al., 1987; Drewes et al., 
1992; Goedert et al., 1997; Hanger et al., 1992; Morishima-Kawashima et al., 1995). 
Tau hyperphosphorylation can also be induced by decreased dephosphorylation. Several 
protein phosphatases (PPs), including PP1, PP2A, PP2B, and PP5, catalyze tau 
dephosphorylation (Drewes et al., 1993; Liu et al., 2005). The appearance of tau 
hyperphosphorylation in the brain reflects an early stage of AD (Maccioni et al., 2010).  
www.intechopen.com
 
Insulin Resistance and Alzheimer’s Disease 
 
61 
Insulin and IGF-1 are related to the phosphorylation state of tau (Table 1). Transient insulin 
treatment increases tau phosphorylation temporarily, correlating with the sequential 
activation and deactivation of GSK3ǃ in SH-SY5Y cells (Lesort et al., 1999). Further, tau 
phosphorylation in primary cortical neurons is regulated by insulin and IGF-1 (Lesort and 
Johnson, 2000). In IRS-2 knockout mice, defects in IRS-2 signaling promotes neuronal death 
and induces the hyperphosphorylation of tau, suggesting that tau-mediated 
neurodegeneration is regulated by the IRS-2 branch of the insulin-IGF signaling pathway 
(Schubert et al., 2003).  
Neuron-specific deletion of insulin receptor (neuronal/brain-specific insulin receptor 
knockout (NIRKO)) in mice leads to tau hyperphosphorylation (Schubert et al., 2004). 
However, the patterns of phosphorylation in NIRKO mice and IRS-2 knockout mice differ, 
suggesting that tau phosphorylation is regulated not only by insulin resistance, but also by 
other factors (e.g., hyperinsulinemia, hyperglycemia, inflammation) (Schubert et al., 2003; 
Schubert et al., 2004). There are other evidences on the relationship between insulin 
signaling and tau hyperphosphorylation. In IGF-1 knockout mice, tau is 
hyperphosphorylated at Ser202 and Ser396, implicating IGF-1 as protective against tau 
hyperphosphorylation (Cheng et al., 2005). Separately, the peripheral administration of 
insulin induced site-specific tau phosphorylation (at Ser202), which occurred rapidly after 
acute insulin administration but prolonged (Freude et al., 2005).  
4.4 Insulin resistance and oxidative stress 
The increase in oxidative stress and the resulting activation of many signaling pathways are 
associated with AD (Markesbery and Carney, 1999; Nunomura et al., 2001).  
Oxidative stress is manifested by damage to proteins (Smith et al., 1991; Smith et al., 1996), 
lipids (Sayre et al., 1997), and nucleic acids (DNA, RNA) (Gabbita et al., 1998; Mecocci et al., 
1994; Nunomura et al., 1999). In AD, neurons that show increased oxidative damage have 
significantly more mtDNA, indicating that mtDNA sustains high oxidative stress in AD 
(Hirai et al., 2001). 
Mitochondria from the brains of AD patients experience structural damage and are the site 
of Aǃ accumulation (Gouras et al., 2005; Hirai et al., 2001). Further, important mitochondrial 
enzymes become impaired in the brains of AD transgenic mice (Caspersen et al., 2005). 
Dysregulated mitochondria release oxidizing free radicals, with peroxidation of membrane 
lipids and the output of toxic aldehydes that cause considerable oxidative stress in AD 
(Smith et al., 1996). 
Oxidative stress is a common feature in AD and insulin resistance. In Drosophila, oxidative 
stress increases signaling through c-Jun N-terminal kinase (JNK), which is a related pathway 
of AD and insulin resistance (Ozcan et al., 2004). Hydrogen peroxide-induced JNK activation 
induces Ǆ-secretase activation, and increases Aǃ generation (Shen et al., 2008). Insulin 
resistance leads to greater oxidative stress, DNA damage, mitochondrial dysfunction, and, 
ultimately, cell death (de la Monte, 2009). In AD patient brains, the expression of pro-oxidant 
enzymes that catalyze the generation of reactive nitrogen (RNS) and oxygen species (ROS), 
such as nitric oxide synthase (NOS) and NADPH oxidase (NOX), rises significantly, which 
accelerates insulin resistance in the brain (de la Monte and Wands, 2006).  
4.5 Insulin resistance and inflammation 
There are many reports that inflammation mediates the progress of AD. In brains of AD 
model mice and AD patients, Aǃ plaque and NFTs activate astrocytes and microglia, 
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resulting in the release of inflammatory molecules (cytokines and chemokines) and the 
production of complement, and ultimately causing neuroinflammation (Eikelenboom et al., 
2002; Hoozemans et al., 2002; McGeer and McGeer, 2003; Tansey et al., 2007). In fact, in AD, 
neurons themselves induce the production of inflammatory molecules, such as interleukin 
(IL)-1, IL-6, TNF-ǂ, and complement proteins (Li et al., 2000; Tchelingerian et al., 1996; Yu et 
al., 2002).Further, Aǃ can attract and activate microglia, affecting the recruitment of 
microglia to Aǃ plaques, and increase the secretion of proinflammatory molecules, such as 
IL-1, IL-6, and IL-8 (Rogers and Lue, 2001). Astrocytes are also activated by Aǃ peptide to 
produce proinflammatory cytokines and chemokines in AD (Smits et al., 2002). Conversely, 
inflammatory cytokines, such as IL-6, regulate APP processing, resulting in elevation of 
Aǃ42 levels (Papassotiropoulos et al., 2001). 
 
 
Fig. 3. Schematic representation of molecular pathways linking insulin resistance and 
Alzheimer disease. Peripheral insulin resistance leads to decrease insulin signaling in CNS, 
followed by alteration in brain metabolism. Increased Aǃ toxicity, Tau 
hyperphosphorylation, oxidative stress and neuroinflammation are attributed to central 
insulin resistance, which leads to neurodegeneration. 
Chronic administration of insulin induces inflammatory responses, although low doses of 
insulin is anti-inflammatory (Krogh-Madsen et al., 2004), suggesting that insulin contributes 
to inflammation. Several reports have noted that insulin modulates many inflammatory 
networks. Co-administration of insulin and lipopolysaccharide has a synergistic effect on 
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the release of inflammatory cytokines, such as IL-1ǃ and IL-6 (Soop et al., 2002). Insulin can 
regulate norepinephrine uptake in the locus coeruleus by modulating the expression of 
norepinephrine transporter protein (NET) (Figlewicz et al., 1993). Because norepinephrine is 
an endogenous anti-inflammatory neuromodulator that prevents IL-1ǃ expression (Heneka 
et al., 2002), chronic administration of insulin might have abnormal inflammatory effects. 
5. Clinical studies on insulin resistance and AD 
Much evidence suggests that insulin resistance and peripheral hyperinsulinemia are risk 
factors for AD, implicating them as novel targets (Craft, 2005; Watson and Craft, 2003). For 
example, optimal doses of insulin and glucose in patients with AD improve declines in 
cognition (Watson et al., 2005). Using hyperinsulinemic-euglycemic clamps, intravenous 
insulin infusion in older subjects and in AD patients improves memory (Craft et al., 2003). 
Recently, intranasal administration of insulin was shown to improve cognitive function and 
modulate APP processing, resulting in increased Aǃ40/Aǃ42 ratio (Reger et al., 2008). 
 
1. Aβ metabolism
Insulin increases the extracellular level of Aǃ by promoting its secretion. (Gasparini et al., 
2001) 
Insulin increases the extracellular level of Aǃ by inhibiting its degradation via 
insulin-degrading enzyme (IDE). 
(Gasparini et al., 
2001) 
Chronic treatment with IGF-1 increases Aǃ production by switching from 
TrkA to p75NTR. 
(Costantini et al., 
2006) 
IGF-1 reduces BACE-1 expression in PC12 cells via activation of PI3K and 
ERK1/2 signaling pathways. 
(Zhang et al., 2011) 
IGF-1 enhanced APP phosphorylation at Thr668, contributing to the neuronal 
degeneration in AD. 
(Araki et al., 2009; 
Chang et al., 2006) 
Infusion of insulin under glucose clamp originated a rapid increase in CSF Aǃ 
levels in older subject 
(Watson and Craft, 
2003) 
Systemic administration of IGF-1 increases CSF Aǃ levels. (Carro et al., 2002) 
IGF-1 increases neuronal excitability and release of Aǃ is enhanced by 
neuronal activity. 
(Gomez, 2008) 
2. Tau hyperphosphorylation 
Insulin and IGF-1 treatment results in increase in tau phosphorylation in 
primary cortical neurons. 
(Lesort and 
Johnson, 2000) 
Peripheral administration of insulin induces site-specific tau phosphorylation 
(Ser202). 
(Freude et al., 2005) 
In IGF-1 knockout mice, tau is hyperphosphorylated at Ser202 and Ser396. (Cheng et al., 2005) 
In IRS-2 knockout mice, IRS-2 regulates tau-mediated neurodegeneration. 
(Schubert et al., 
2003) 
Neuronal/brain-specific insulin receptor knockout (NIRKO) in mice leads to 
tau hyperphosphorylation. 
(Schubert et al., 
2004) 
 
Table 1. The direct role for insulin or IGF-1 as a possible mediator of AD. 
In addition to insulin, insulin-sensitizing compounds have been used as pharmacological 
treatments. Thiazolidinediones (TZDs) act as agonists of nuclear receptor PPAR-Ǆ 
(peroxisome proliferator-activated receptor-gamma) and improve insulin sensitivity by 
reducing circulating insulin, FFA levels, and glucose uptake. TZDs are also anti-
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inflammatory drugs that decrease the levels of many inflammatory mediators (Jiang et al., 
2008; Neumann et al., 2008; Rojo et al., 2008). Pioglitazone and rosiglitazone are some of the 
TZDs that are available for clinical use. The dual function of TZDs also affects hallmarks of 
AD pathogenesis, such as Aǃ levels and tau hyperphosphorylation. PPAR-Ǆ agonists, such 
as pioglitazone and indomethacin, can regulate Aǃ42 levels and Aǃ plaque loads (Heneka et 
al., 2005; Sastre et al., 2003). 
Troglitazone decreases tau phosphorylation at Ser202 and Ser396/404 through a PPAR-Ǆ-
dependent/independent mechanism (d'Abramo et al., 2006). In a recent report, rosiglitazone 
reduced tau phosphorylation through JNK inhibition (Yoon et al., 2010).  
TZDs improve memory in animal models and patients with AD. Rosiglitazone, a TZD, 
attenuates learning and memory deficits in Tg2576 mouse, an animal model of AD 
(Pedersen et al., 2006). Recently, pioglitazone was noted to preserve cognitive function in 
AD (Sato et al., 2009). This pilot study on 42 patients who were treated with 15-30 mg 
pioglitazone daily or placebo observed cognitive improvement in the pioglitazone groups. 
In another study, 511 AD patients were assigned to receive 2, 4, or 8 mg rosiglitazone 
(rosiglitazone group) or nothing (control group) (Risner et al., 2006); the rosiglitazone group 
improved cognition significantly, and this result was restricted to non-APOE ε4 carriers.  
Insulin-sensitizing hormones, such as ghrelin, also affect AD pathogenesis. Ghrelin is a 28-
amino-acid endogenous hormone that is a ligand of growth hormone secretagogue receptor 
1a (GHSR-1a) (Kojima et al., 1999). Several studies have shown that ghrelin reduces tau 
hyperphosphorylation in high-glucose-induced neurons (Chen et al., 2010), and ghrelin 
enhances hippocampus-dependent memory in rodents (Carlini et al., 2010). Recently, Moon 
et al. observed that ghrelin ameliorates cognitive dysfunction in oligomeric Aǃ42-injected 
mice (Moon et al., 2011). These and other reports demonstrate that brain insulin resistance 
leads to AD pathologies and thus suggest that insulin-sensitizing agents, such as the TZDs 
and ghrelin, are useful therapeutic agents. 
6. Conclusion 
Insulin resistance is characterized by chronic peripheral insulin elevations, central reduction 
of insulin levels and abnormality of insulin activity. Insulin modulates not only peripheral 
glucose metabolism but also normal brain function, and thereby conditions related to 
insulin dysregulation, such as obesity and diabetes mellitus, have deleterious effects on 
brain function. According to recent longitudinal studies, insulin resistance increases the risk 
of memory deficit and AD. Potential mechanisms linking insulin resistance to AD 
pathogenesis include the alteration in APP processing, defects in signal transduction related 
to both neuronal function (e.g. GSK3ǃ) and cellular toxicity including oxidative stress and 
inflammation. Identification of underlying mechanisms for relevance of insulin resistance to 
AD is exigent goal to develop effective therapeutic strategies targeting AD. Many evidences 
have noted that agents modulating insulin resistance, including TZDs and insulin-
sensitizing hormones, alleviate cognitive impairments associated with AD. Therapeutic 
strategies focused on preventing or regulating insulin resistance may thus benefit the 
development of drugs for AD. 
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